Front Page News

Cure SMA-Funded Researcher, Chad Heatwole, Publishes Paper on SMA-HI, a Clinical Trial Outcome in Adults with SMA

March 23, 2021
Posted in ,

Dr. Chad Heatwole, a Cure SMA-funded researcher, and his team have published a paper in the Journal, Muscle Nerve, titled “The Spinal Muscular Atrophy Health […]

Read More ›

Nusinersen Research Updates Presented by Biogen

March 19, 2021
Posted in , ,

Biogen recently presented data about ongoing studies of SPINRAZA (nusinersen) in patients with Spinal Muscular Atrophy. Updates included the NURTURE, ENDEAR, SHINE, DEVOTE, and RESPOND […]

Read More ›

Research Updates from Scholar Rock

March 19, 2021
Posted in , ,

Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in SMA Scholar Rock recently shared 6-month interim analysis data from the TOPAZ Phase 2 clinical […]

Read More ›

Community Statement from Genentech

March 18, 2021
Posted in ,

Dear SMA Community, Based on our commitment to the SMA community to provide transparent, timely updates related to our medicines, we are writing to share […]

Read More ›

Community Statement from Novartis Gene Therapies

March 18, 2021
Posted in ,

Dear Cure SMA Community, Novartis Gene Therapies is committed to patient safety and the ongoing monitoring of adverse events as it relates to the use […]

Read More ›

Evrysdi Research Updates from Genentech

March 18, 2021
Posted in , ,

New 2-year data show Evrysdi continues to demonstrate improvement or maintenance of motor function in people aged 2-25 years with Type 2 or 3 SMA […]

Read More ›

Zolgensma Research Updates from Novartis Gene Therapies

March 18, 2021
Posted in , ,

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children, and durability 5+ years post-treatment Novartis Gene Therapies recently shared new […]

Read More ›

Cure SMA Publishes Quality of Life in Teens and Young Adults Manuscript in Orphanet Journal of Rare Diseases

March 11, 2021
Posted in ,

Current knowledge regarding clinical meaningfulness and quality of life amongst teens and young adults with spinal muscular atrophy (SMA) is limited. Much of the available […]

Read More ›

Biogen SMA Q1 2021 Community Statement

March 8, 2021
Posted in ,

      Dear Members of the SMA Community, Each year, the entire rare disease community comes together on the last day of February to […]

Read More ›

Community Spotlight: I am…Viola Dwyer

February 26, 2021
Posted in ,

February 28 is Rare Disease Day. Throughout the month—in recognition of our Redefining Rare initiative—we have been posting stories about SMA community members, showcasing their […]

Read More ›
Scroll to Top